Rationale for Increasing the Starting Dose of Simvastatin.

Clin Drug Investig

Charleston Area Medical Center, Health Education and Research Institute and West Virginia University, Charleston, West Virginia, USA.

Published: September 2002

Download full-text PDF

Source
http://dx.doi.org/10.2165/00044011-200222090-00009DOI Listing

Publication Analysis

Top Keywords

rationale increasing
4
increasing starting
4
starting dose
4
dose simvastatin
4
rationale
1
starting
1
dose
1
simvastatin
1

Similar Publications

Rationale: Peliosis hepatis (PH) is a rare disease with few clinical reports and complex etiology. However, there have been no reports of hyperprolactinemia (HPRL) leading to PH at present. This paper, through case reports, expands the understanding of the etiology of PH and the pathological damage effect of prolactin (PRL).

View Article and Find Full Text PDF

Rationale: Solitary fibrous tumors (SFTs) are spindle cell tumors that typically occur in the pleura and peritoneum, but very rarely in the stomach. To our best knowledge, there are only 10 cases reported in English literature. We reported a case of primary stomach SFT and summarized the characteristics of all previous cases, suggesting that pathologists and surgeons should include this disease in the differential diagnosis list of primary mesenchymal tumor of the stomach.

View Article and Find Full Text PDF

Rationale: Spontaneous retroperitoneal hematoma (SRH) is a rare but potentially fatal condition, often associated with anticoagulation therapy. With the global prevalence of COVID-19 and the widespread use of anticoagulants in its management, there is an increasing need to recognize rare but serious complications like SRH. This case report aims to emphasize the importance of early recognition and intervention of SRH in patients with COVID-19 undergoing anticoagulation therapy, to improve patient outcomes and reduce mortality.

View Article and Find Full Text PDF

Optimizing Exclusion Criteria for Clinical Trials of Persistent Lyme Disease Using Real-World Data.

Healthcare (Basel)

December 2024

Union Square Medical Associates, 595 Buckingham Way, Suite 350, San Francisco, CA 94132, USA.

Background/objectives: Although eligibility criteria for clinical trials significantly impact study outcomes, these criteria are often established without scientific justification, leading to delayed recruitment, small sample sizes, and limited study generalizability. Persistent Lyme disease (PLD) presents unique challenges due to symptom variability, inconsistent treatment responses, and the lack of reliable biomarkers, underscoring the need for scientifically justified eligibility criteria.

Objective: This study examines the effects of commonly used enrollment criteria on sample yield in PLD clinical trials using real-world data (RWD) from the MyLymeData patient registry.

View Article and Find Full Text PDF

Rationale & Objective: Peritoneal dialysis (PD) solutions provide both clearance of uremic toxins and sodium and water. An intraperitoneal (IP) solution of icodextrin and glucose designed without the requirement for uremic toxin clearance could provide substantially greater sodium and water removal than PD solutions.

Study Design: We examined varying concentrations of icodextrin and dextrose IP solutions in rats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!